33365-53-6

Basic information

• Product Name: Phenol, 4-[(1E)-2-[4-(dimethylamino)phenyl]ethenyl]-
• Synonyms: 4-N,N'-dimethylamino-4'-hydroxylstilbene
• CAS NO: 33365-53-6
• Molecular Formula: C16H17NO
• Molecular Weight: 239.317
• Mol File: 33365-53-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Phenol, 4-[(1E)-2-[4-(dimethylamino)phenyl]ethenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-[(1E)-2-[4-(dimethylamino)phenyl]ethenyl]-(33365-53-6)
• EPA Substance Registry System: Phenol, 4-[(1E)-2-[4-(dimethylamino)phenyl]ethenyl]-(33365-53-6)

Safety Data

• Hazardous Substances Data: 33365-53-6(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 18951-43-4 4-Amino-4'-hydroxy-stilbene 
• 33365-52-5 4-[(E)-2-(4-Methoxymethoxy-phenyl)-vinyl]-phenylamine 
• 74-88-4 methyl iodide 

Downstream Products

• 902143-21-9 [4-(2-{4-[2-(4-bromobenzyl)-3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}vinyl)phenyl]dimethylamine 
• 902143-04-8 4-N,N'-dimethylamino-4'-(2,2-dimethyl-[l,3]dioxane-5-ylmethoxy)stilbene 

Relevant articles and documents

NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds

F-18 stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain

Imaging agents targeting β-amyloid (Aβ) may be useful for diagnosis and treatment of patients with Alzheimer's disease (AD). Compounds 3e and 4e are fluorinated stilbene derivatives displaying high binding affinities for Aβ plaques in AD brain homogenates (Ki = 15 ± 6 and 5.0 ± 1.2 nM, respectively). In vivo biodistributions of [ 18F]Se and [18F]4e in normal mice exhibited excellent brain penetrations (5.55 and 9.75% dose/g at 2 min), and rapid brain washouts were observed, especially for [18F]4e (0.72% dose/g at 60 min). They also showed in vivo plaque labeling in APP/PS1 or Tg2576 transgenic mice, animal models for AD. Autoradiography of postmortem AD brain sections and AD homogenate binding studies confirmed the selective and specific binding properties to Aβ plaques. In conclusion, the preliminary results strongly suggest that these fluorinated stilbene derivatives, [18F]3e and [18F]4e, are suitable candidates as Aβ plaque imaging agents for studying patients with AD.